CLOs on the Move

ConjuGon Inc

www.conjugon.com

 
ConjuGon Inc is a Madison, WI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.conjugon.com
  • University Research Park 505 S Rosa Rd Ste 29
    Madison, WI USA 53719
  • Phone: 608.441.2890

Executives

Name Title Contact Details

Similar Companies

Allylix Inc.

Allylix Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Scorpion Therapeutics

Scorpion Therapeutics was founded to expand the reach of precision medicine to more people with cancer.

Entelo

Entelo applies intelligence to big data to help modern recruiters identify, qualify and engage talent. Today, more than 700 customers of all sizes and industries trust Entelo to provide their talent acquisition teams with higher candidate engagement, actionable insights and increased productivity. The leader in recruiting automation, Entelo helps organizations like Capital One, Cisco, GE, Genentech, Netflix, Northrop Grumman and Target build their teams.

Concentric Analgesics

Concentric Analgesics, Inc. is a private, biotechnology company focused on discovering and developing novel, non-opioid therapeutics for the management of acute and chronic pain.

Omega Therapeutics

Omega Therapeutics is a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming™ platform. The OMEGA™ platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism`s life from cell genesis, growth and differentiation to cell death. The OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega`s engineered, modular, and programmable mRNA-encoded epigenetic medicines, Omega Epigenomic Controllers™, target specific intervention points amongst the thousands of mapped and validated novel DNA-sequence-based epigenomic loci to durably tune single or multiple genes to treat and cure disease through Precision Genomic Control™. Omega is currently advancing a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.